ID   Sui69
AC   CVCL_UM54
DR   cancercelllines; CVCL_UM54
DR   GEO; GSM4767167
DR   IARC_TP53; 26971
DR   JCRB; JCRB1919
DR   Wikidata; Q98132872
RX   PubMed=18691340;
RX   PubMed=35272288;
CC   Population: Japanese.
CC   Characteristics: Established from the 69Taco6 SCID nude mouse xenograft.
CC   Senescence: Has a finite life span (JCRB=JCRB1919).
CC   Doubling time: 55.2 hours (PubMed=18691340); 35.5 hours (PubMed=35272288).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=35272288).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=18691340; PubMed=35272288).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=18691340; PubMed=35272288).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): JCRB=JCRB1919
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 10,12
ST   D5S818: 10
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   54Y
CA   Finite cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=18691340; DOI=10.1111/j.1349-7006.2008.00896.x; PMCID=PMC11158226;
RA   Yanagihara K., Takigahira M., Tanaka H., Arao T., Aoyagi Y., Oda T.,
RA   Ochiai A., Nishio K.;
RT   "Establishment and molecular profiling of a novel human pancreatic
RT   cancer panel for 5-FU.";
RL   Cancer Sci. 99:1859-1864(2008).
//
RX   PubMed=35272288; DOI=10.1159/000521714;
RA   Yanagihara K., Iino Y., Yokozaki H., Kubo T., Oda T., Kubo T.,
RA   Komatsu M., Sasaki H., Ichikawa H., Kuwata T., Seyama T., Ochiai A.;
RT   "A comparative study of patient-derived tumor models of pancreatic
RT   ductal adenocarcinoma involving orthotopic implantation.";
RL   Pathobiology 89:222-232(2022).
//